PerMed Biosciences Announces Financial and Business Information Due to Securities Trading Alert Threshold on Centralized Market

1. Date of Event: 2026/06/18

2. Reason for Disclosure: In accordance with notification from the Taiwan Stock Exchange Corporation

3. Financial and Business Information:

The consolidated financial data of the Company is as follows:

Most Recent Month vs. Same Month Last Year Most Recent Quarter vs. Same Quarter Last Year Cumulative Last Four Quarters Consolidated Self-Reported % Change Consolidated Reviewed % Change Consolidated Audited/Reviewed (May 2026) (Q1 2026) (Q2 2025 to Q1 2026)

Revenue 2,690 (NT$ thousands) 18.76% 6,368 (NT$ thousands) (46.68%) 25,848 (NT$ thousands)

Pre-tax Net -28,298 (NT$ thousands) (17.45%) -87,174 (NT$ thousands) (12.83%) -462,588 (NT$ thousands) Loss

Net Loss Attributable -24,825 (NT$ thousands) (12.46%) -76,584 (NT$ thousands) (1.08%) -424,754 (NT$ thousands) to Owners of the Parent

Earnings Per -0.38 (NT$) 0.00% -1.18 (NT$) 9.23% -7.11 (NT$) Share

4. Whether there are material events under Article 4 of the 'Taiwan Stock Exchange Corporation Procedures for Verification and Public Disclosure of Material Information by Listed Companies': No

5. Whether there is a requirement to hold a press conference under Article 11 of the above procedures: No

6. For complete financial information, please visit the Public Information Observation Station via the following paths:

(1) Recent operating revenue and profit/loss information: Basic Information > Summary Version

(2) Historical monthly operating revenue: Operations Overview > Monthly Revenue > Monthly Operating Revenue Information under IFRS

(3) Historical profit/loss (audited/reviewed by accountants): Financial Statements > Under IFRS > Consolidated/Individual Statements > Comprehensive Income Statement

(4) Historical profit/loss (voluntary self-reported figures): Operations Overview > Self-Reported Profit/Loss Announcement: Not Applicable

7. Other Matters to be Disclosed: None